Skip to main content
PreveCeutical Medical logo

PreveCeutical Medical — Investor Relations & Filings

Ticker · PREV ISIN · CA74143C1068 LEI · 96760001OJCSH5MXZ450 CSE Professional, scientific and technical activities
Open in API
Filings indexed 438 across all filing types
Latest filing 2021-11-24 Regulatory Filings
Country CA Canada
Listing CSE PREV

About PreveCeutical Medical

https://www.preveceutical.com/

PreveCeutical Medical Inc. is a health sciences company dedicated to the research and development of innovative options for preventive and curative therapies. The company specializes in utilizing organic and nature identical products, combining scientific rigor with natural sources to benefit health-conscious consumers. Its primary focus is on the preventive health sector, collaborating with partners to bring novel solutions to market.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a provisional patent application by PreveCeutical Medical Inc. It discusses the patent application details, the company's research programs, and forward-looking statements. There is no indication of financial data, regulatory filings, management changes, or any of the other specific report types. The document is an announcement of a corporate event (patent filing) rather than a financial or regulatory report. Therefore, it best fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2021-11-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PreveCeutical Medical Inc. has signed a license agreement for exclusive rights to use UniQuest's Sol-Gel technology for cannabinoid delivery. It contains no financial statements, no regulatory form references, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. The content is primarily a business update about a licensing agreement and forward-looking statements. It is not a report, transcript, or regulatory filing but a corporate announcement. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS). The document length is 8629 characters, which is substantial but the content is clearly an announcement rather than a report or detailed financial document. Confidence is high due to clear content type and absence of other category indicators.
2021-11-18 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Caroline MacCallum as a senior advisor and consultant to PreveCeutical Medical Inc. It focuses on management changes and additions, specifically the addition of a senior advisor with expertise relevant to the company's business. There is no financial data, no mention of financial results, no regulatory filings, or report publications. The content is about a change in the company's management or advisory team. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 8240 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data.
2021-10-05 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PreveCeutical Medical Inc. has received a cash refund from the Australian Federal Government's Research and Development Tax Incentive Program. It discusses the amount received, the purpose of the funding, and the company's R&D activities. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an announcement of a financing-related event (receipt of a government cash refund related to R&D activities). It is not an annual report, earnings release, or detailed financial report. The content fits best under Capital/Financing Update (CAP) as it relates to a cash inflow from a government incentive program that impacts the company's capital and funding situation.
2021-08-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2021-08-30 English
Interim MD&A - English.pdf
Regulatory Filings
2021-08-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.